Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate

Thrombosis and Haemostasis

Volumn 100, Issue 3, 2008, Pages 420-428

  Glauser, Bianca F ^a   Pereira, Mariana S ^a   Monteiro, Robson Q ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Glycosaminoglycan; Heparin; Prothrombinase complex; Sea cucumber; Tenase complex

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CHONDROITIN SULFATE; GLUCOSE; GLUCURONIC ACID; HEPARIN; HEPARIN COFACTOR II; SERINE PROTEINASE INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; ENZYME INHIBITION; FUCOSYLATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 51349116958     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0210     Document Type: Article

References (37)

1. American Heart Association 2002. Heart and Stroke. Statistical update.
2. Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg. 2007; 15: 148-155.
3. Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 9: 225-232.
4. Farias WRL, Valente AP, Pereira MS, et al. Structure and anticoagulant activity of sulfated galactans - Isolation of a unique sulfated galactan from the red algae Botryocladia occidentalis and comparison of its anticoagulant action with that of sulfated galactans from invertebrates. J Biol Chem 2000; 275: 29299-29307.
5. Mulloy B, Mourão PA, Gray E. Structure/function studies of anticoagulant sulphated polysaccharides using NMR. J Biotechnol 2000; 77: 123-135.
6. Mourão PA, Pereira MS, Pavão MS, et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. J Biol Chem 1996; 271: 23973-23984.
7. Pacheco RG, Vicente CP, Zancan P, et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinolysis 2000; 11: 563-573.
8. Fonseca RJC, Mourão PAS. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
9. Zancan P, Mourão PA. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coagul Fibrinolysis 2004; 15: 45-54.
10. Astermark J, Hogg PJ, Bjork I, et al. Effects of gamma-carboxyglutamic acid and epidermal growth factor-likemodules of factor IX on factor X activation. Studies using proteolytic fragments of bovine factor IX. J Biol Chem 1992; 267: 3249-3256.
11. Ngai PK, Chang JY. A novel one-step purification of human alpha-thrombin after direct activation of crude prothrombin enriched from plasma. Biochemistry J 1991; 280: 805-806.
12. Barrow RT, Parker ET, Krishnaswamy S, et al. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-26800.
13. Pereira MS, Melo FR, Mourão PAS. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? Glycobiology 2002; 12: 573-580.
14. Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67: 3-12.
15. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988; 53: 505-518.
16. Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78: 1637-1651.
17. Rezaie AR. Heparin-binding exosite of factor Xa. Trends Cardiovasc Med 2000; 10: 333-338.
18. Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA) 1994; 91: 5518-5522.
19. Rezaie, AR. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem 2000; 275: 3320-3327.
20. Sheehan JP, Walke EN. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin- independent mechanism. Blood 2006; 107: 3876-3882.
21. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
22. Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182.
23. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006: 450-456.
24. Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis 2006; 21: 67-72.
25. Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag 2007; 3: 321-329.
26. Eriksson BI, Dahl OE, Büller HR, et al.; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
27. Holrner E. In: Heparin. Chemical and biological properties, clinical applications. 1989; 575-595.
28. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920.
29. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
30. Thomas DP, Merton RE, Barrowcliffe TW, et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248.
31. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
32. Hockin MF, Jones KC, Everse SJ, et al. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-18333.
33. Anderson JA, Fredenburgh JC, Stafford AR, et al. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J Biol Chem 2001; 276: 9755-9761.
34. Sie P, Ofosu F, Fernandez F, et al. Active role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulfated polysaccharides. Br J Haematol 1986; 64: 707.
35. Nagase H, Enjyoji K, Minamiguchi K, et al. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995; 85: 1527-1534.
36. Buchanan MR, Ofosu FA, Fernandez F, et al. Lack of relationship between enhanced bleeding induced by heparin and other sulfated polysaccharides and enhanced catalysis of thrombin inhibition. Semin Thromb Hemost 1986; 12: 324-327.
37. He L, Vicente CP, Westrick RJ, et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.